Journal
JOURNAL OF IMMUNOLOGY
Volume 208, Issue 6, Pages 1371-1377Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.2100352
Keywords
-
Categories
Ask authors/readers for more resources
CD47 blockade is a promising immuno-oncology treatment that promotes clearance of cancer cells, but it also leads to depletion of splenic marginal zone B cells, which is dependent on intact CD47-SIRP alpha interactions.
CD47 is an important innate immune checkpoint through its interaction with its inhibitory receptor on macrophages, signal-regulatory protein alpha (SIRP alpha). Therapeutic blockade of CD47-SIRP alpha interactions is a promising immuno-oncology treatment that promotes clearance of cancer cells. However, CD47-SIRP alpha interactions also maintain homeostatic lymphocyte levels. In this study, we report that the mouse splenic marginal zone B cell population is dependent on intact CD47-SIRP alpha interactions and blockade of CD47 leads to the loss of these cells. This depletion is accompanied by elevated levels of monocyte-recruiting chemokines CCL2 and CCL7 and infiltration of CCR2(+)Ly6C(hi) monocytes into the mouse spleen. In the absence of CCR2 signaling, there is no infiltration and reduced marginal zone B cell depletion. These data suggest that CD47 blockade leads to clearance of splenic marginal zone B cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available